Article thumbnail

Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF

By Hanna Björkelund, Lars Gedda, Pavel Barta, Magnus Malmqvist and Karl Andersson

Abstract

The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR). Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefitinib increases the affinity for some cell lines. In this paper, we investigate possible mechanisms behind these observations. Real-time interaction analysis in LigandTracer® Grey revealed that the HER2 dimerization preventing antibody pertuzumab clearly modified the binding of 125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of gefitinib. Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2. Cross-linking measurements showed that gefitinib increased the amount of EGFR dimers 3.0–3.8 times in A431 cells in the absence of EGF. In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8–2.2 times by gefitinib, but this effect was cancelled by pertuzumab. Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3. Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered the different components of the measured interaction and supports EGF binding to multiple binding sites. EGFR and HER2 expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/dimeric forms of EGFR with unique binding properties. Taken together, we conclude that dimerization explains the varying affinity of EGF – EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction characteristics with 125I-EGF

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3171474
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1996). A hierarchical network of interreceptor interactions determines signal transduction Gefitinib Induce EGFR Dimers -
  2. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
  3. (2008). All EGF(ErbB) receptors have preformed homoand heterodimeric structures in living cells.
  4. (2004). Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.
  5. (2006). Automated, high-resolution cellular retention and uptake studies in vitro.
  6. (2011). Avoiding false negative results in specificity analysis of protein-protein interactions.
  7. (1999). Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
  8. (2011). Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun In
  9. (2003). Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria.
  10. (2011). Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
  11. (1991). Dimerization of internalized epidermal growth factor receptors.
  12. (2010). Effect of cetuximab treatment in squamous cell carcinomas.
  13. (1982). Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells.
  14. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
  15. (1987). Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.
  16. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer.
  17. (2000). Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
  18. (1978). Epidermal growth factor: biological activity requires persistent occupation of high-affinity cell surface receptors.
  19. (2008). ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
  20. (2008). Fernandez A
  21. (1989). Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules.
  22. (2000). HER2/neu: mechanisms of dimerization/oligomerization.
  23. (1989). High-yield trapping of EGF-induced receptor dimers by chemical cross-linking.
  24. (2007). Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy.
  25. (2010). Kinase-mediated quasi-dimers of EGFR.
  26. (2010). Ligand binding assays at equilibrium: validation and interpretation.
  27. (2008). Method for the analysis of solid biological objects. Patent application WO
  28. (2006). On the nature of low- and high-affinity EGF receptors on living cells.
  29. (2009). Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
  30. (1962). Preparation of iodine-131 labeled human growth hormone of high specific activity.
  31. (1990). Signal transduction by receptors with tyrosine kinase activity.
  32. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.
  33. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
  34. (2006). Targeting tyrosine kinases in cancer: the second wave.
  35. (2007). The EGF receptor family: spearheading a merger of signaling and therapeutics.
  36. (2001). The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
  37. (2008). Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
  38. (2001). Untangling the ErbB signalling network.
  39. (2002). ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.